Search hospitals > Illinois > Mount Vernon

Good Samaritan Regional Health Center

Claim this profile
Mount Vernon, Illinois 62864
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Breast cancer
Conducts research for Cancer
Conducts research for Ovarian Cancer
336 reported clinical trials
1 medical researcher
Photo of Good Samaritan Regional Health Center in Mount VernonPhoto of Good Samaritan Regional Health Center in Mount VernonPhoto of Good Samaritan Regional Health Center in Mount Vernon

Summary

Good Samaritan Regional Health Center is a medical facility located in Mount Vernon, Illinois. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Cancer, Ovarian Cancer and other specialties. Good Samaritan Regional Health Center is involved with conducting 336 clinical trials across 463 conditions. There are 1 research doctors associated with this hospital, such as Jay W Carlson.

Area of expertise

1Breast Cancer
Global Leader
Good Samaritan Regional Health Center has run 64 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
ER positive
HER2 negative
2Lung Cancer
Global Leader
Good Samaritan Regional Health Center has run 47 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II

Top PIs

Clinical Trials running at Good Samaritan Regional Health Center

Lung Cancer
Bladder Cancer
Breast Cancer
Prostate Cancer
Breast cancer
Esophageal cancer
Cancer
Multiple Myeloma
Melanoma
Pancreatic Cancer
Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Image of trial facility.

Chemotherapy + Immunotherapy vs. Immunotherapy

for Advanced Lung Cancer

This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab and chemotherapy may help stabilize lung cancer.
Recruiting2 awards Phase 3
Image of trial facility.

Osimertinib + Bevacizumab

for Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Good Samaritan Regional Health Center?
Where is Good Samaritan Regional Health Center located?
Who should I call to ask about financial aid or insurance network?
What insurance does Good Samaritan Regional Health Center accept?
What awards or recognition has Good Samaritan Regional Health Center received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security